41 results about "Choroid" patented technology

The invention provides a dynamic myopia management lens prescription customization method and system, and relates to the technical field of lens design and customization. According to the dynamic myopia management lens prescription customization technology provided by the invention, ophthalmic basic data of a patient is acquired; then periodically follow-up the patient to obtain ophthalmology measurement follow-up data of the patient; the joint evaluation model dynamically updates a myopia risk evaluation grade of the patient based on ophthalmology basic data and ophthalmology measurement follow-up visit data; and finally, dynamically updating the lens prescription based on the myopia risk assessment level of each time by the joint assessment model. According to the technical scheme, the combined evaluation model can perform dynamic lens prescription adjustment according to follow-up visit ocular axis progress and choroid change conditions, dynamic myopia management lens prescription customization, whole-course tracking of a myopia cycle and individualized prevention and control management are realized, and thus the effectiveness and continuity of myopia prevention and control are improved.

An apparatus for delivering therapeutic agent to an eye comprises a body, a cannula, a hollow needle, and an actuation assembly. The cannula extends distally from the body and is sized and configured to be insertable between a choroid and a sclera of a patient's eye. The actuation assembly is operable to actuate the needle relative to the cannula to thereby drive a distal portion of the needle along an exit axis that is obliquely oriented relative to the longitudinal axis of the cannula. The cannula may be inserted through a sclerotomy incision to position a distal end of the cannula at a posterior region of the eye, between the choroid and sclera. The needle may be advanced through the choroid to deliver the therapeutic agent adjacent to the potential space between the neurosensory retina and the retinal pigment epithelium layer, adjacent to the area of geographic atrophy.

The present application relates to the field of traditional Chinese medicine, in particular to a kind of traditional Chinese medicine composition for treating central serous chorioretinopathy and application thereof.The present application provides a kind of traditional Chinese medicine composition for treating central serous chorioretinopathy, compared with the prescription of Chunzai Decoction, the traditional Chinese medicine composition of the present application increases the efficacy of promoting blood circulation and removing blood stasis, soothing the liver and relieving depression, clearing the liver and improving eyesight, clearing heat and reducing phlegm on the basis of Chunzai Decoction warming yang, transforming qi, reducing water and removing dampness;Compared with using Chunzai Decoction alone, the curative effect of patients using the traditional Chinese medicine composition is more direct, from 2-3 weeks to 1 week, and the curative effect is accelerated.And the traditional Chinese medicine composition of the present application has been used for about 2 years, 2 / 3 of the 112 patients can see effect in 1 week, and no recurrence is found within 3 months.

The invention discloses an eye movement guiding device for eye muscle exercise and a using method thereof, and relates to the technical field of vision health care instruments, the eye movement guiding device comprises a shell, a multi-dimensional adjusting mechanism and a sighting mark; the multi-dimensional adjusting mechanism is arranged in the shell, the sighting mark is arranged on the multi-dimensional adjusting mechanism, and the multi-dimensional adjusting mechanism drives the sighting mark to move in the shell; wherein the multi-dimensional adjusting mechanism comprises an X-axis track, a Y-axis track and a Z-axis track; the Y-axis track is arranged in the shell; the X-axis track is arranged on the Y-axis track, and the Y-axis track is used for driving the X-axis track to slide; the Z-axis track is arranged on the X-axis track, and the X-axis track is used for driving the Z-axis track to slide; the sighting mark is arranged on the Z-axis track, the Z-axis track is used for driving the sighting mark to slide, the eyeballs can rotate along with the sighting mark, ciliary muscles, six extraocular muscles and a choroidal system are synchronously activated, the extraocular muscles improve coordination and glancing ability in three-dimensional track movement, and plane fixation stiffness of short-distance eye use is broken.

The invention relates to a saffron crocus eye pad and a method for controlling eye axis growth, and belongs to the technical field of eye care products. The eye patch comprises a patch carrier and a plant extraction gel layer coated on the patch carrier, the plant extract gel layer is composed of mulberry leaf extract, chrysanthemum extract, butterflybush flower extract, amur corktree extract, crocus sativus flower extract, lithospermum extract, madder extract, lycium ruthenicum extract, beet root juice powder, natural borneol, menthol, xanthan gum, purified water and other natural components. The crocus sativus flower extract can enhance the blood flow speed of choroid, thicken the choroid and effectively control the growth of an ocular axis, so that the effect of delaying or improving the development of myopia is achieved. According to the gel layer, a hydrogel structure is formed through xanthan gum, natural borneol and menthol are combined to provide cooling and soothing effects, and the gel layer has good skin affinity and use safety.

An ocular access instrument (20) includes an attachment assembly (32) configured to engage a sclera of an eye, and an actuator assembly (34) configured to bear against the sclera. When the attachment assembly engages the sclera, movement of the actuator assembly inwardly against the eye displaces the choroid from the sclera, thereby creating an enlarged suprachoroidal space. The ocular access instrument may also include a needle guide (40) configured to receive the needle and guide the needle into the enlarged suprachoroidal space.

The invention discloses a pathological myopic lesion classification method, system and device and a medium, belongs to myopic lesion classification in artificial intelligence medicine, and aims to solve the technical problem that choroidal lesion classification accuracy is low due to the fact that diagnosis complexity cannot be captured when multiple pathological myopic lesions exist at the same time are classified in the prior art. The method comprises the following steps: acquiring an OCT sample image and a label, constructing and training a myopic lesion classification model, and performing real-time classification; the myopia lesion classification model comprises a shared encoder, a segmentation decoder and a classification decoder; the shared encoder comprises four residual blocks which are arranged in sequence; the segmentation decoder is a semi-supervised divider; the classification decoder comprises a focus focusing module, a pyramid structure feature fusion module and a classification module which are arranged in sequence. A myopia lesion classification model is creatively constructed, a segmentation decoder can automatically identify a choroid structure in an OCT image, and the blank between a traditional clinical index and a deep learning diagnosis system is effectively filled.

The invention relates to the technical field of lighting equipment, in particular to a negative oxygen ion eye-protection lamp capable of inhibiting myopia and relieving asthenopia, which comprises an eye-protection lamp body, a lamp post and a negative oxygen ion generator, the eye-protection lamp body is used for emitting full-spectrum light; the negative oxygen ion generator is installed at the joint of the eye protection lamp body and the lamp pole, and the concentration of negative oxygen ions generated by the negative oxygen ion generator is 5000-5000 / cm < 3 >. When the eye protection lamp is used, the negative oxygen ion generator is arranged at the joint of the eye protection lamp body and the lamp pole, the negative oxygen ion generator can generate negative oxygen ions with the concentration of 5000-50000 / cm < 3 >, more dopamine is secreted by a living body through the negative oxygen ions, the fundus blood flow density and the fundus retina cell activity are improved, the choroid thickness is increased, and therefore the eye protection effect is improved. Therefore, the visual comfort is improved, and the effects of inhibiting myopia and relieving asthenopia are achieved.

The present application relates to the field of ophthalmic medical technology, especially to an eyeball cornea treatment system based on near-infrared light recognition, which acquires optical information of eyeball cornea and choroid by collecting near-infrared light signals, and performs digitalization and filtering processing on the original image to output processed image data. Combining edge detection and threshold segmentation, choroid defects or atrophic lesion points are identified, and corneal thickness and curvature are measured to determine the energy intensity, irradiation time, wavelength and focusing position of the excimer light beam. According to the parameters, an excimer light beam with a wavelength of 248 nanometers is emitted to irradiate and treat the lesion area, which improves the positioning accuracy of the lesion while avoiding damage to normal tissue structures, and meets the safety and effectiveness requirements of eye treatment.

The invention provides an experimental animal eyeball extraction mark fixing and choroid paving piece positioning device which comprises an annular adjustable ferrule assembly and a square positioning ferrule assembly, the annular adjustable ferrule assembly and the square positioning ferrule assembly are of detachable structures, and the annular adjustable ferrule assembly is connected to the upper surface of the square positioning ferrule assembly in a clamped mode; the annular adjustable ferrule assembly is an annular main body and comprises an adjustable inner ring, the inner diameter of the adjustable inner ring can be elastically adjusted to adapt to eyeballs of different sizes, the technical field of ophthalmology basic experimental animal research equipment is involved, and the inner diameter of the adjustable inner ring of the annular adjustable ferrule assembly can be elastically adjusted to adapt to experimental rodent eyeballs of different sizes. The eyeball marking and taking-out device has the advantages that small eyeballs of young rats and large eyeballs of adult rats can be tightly attached to each other, accordingly, the stability of the eyeballs in marking and taking-out procedures can be guaranteed, eyeball injuries due to improper matching of the ferrules and the eyeballs can be prevented, the application range of the eyeball marking and taking-out device can be expanded, and the universality and the practicability of the eyeball marking and taking-out device can be improved.

The utility model relates to an organ model which comprises a model body with an inner cavity, a plurality of red venation bodies and a plurality of purple venation bodies for simulating blood capillaries are arranged in the side wall of the model body, and the red venation bodies and the purple venation bodies are located on the side close to the inner surface of the model body. The red venation body and the purple venation body are arranged on the inner surface of the model body, so that the red venation body and the purple venation body are visible from the inner surface of the model body, a plurality of surface venation bodies for simulating coarse vessels are arranged on the inner surface of the model body, and a transparent adhesive layer for simulating mucous membranes is arranged on the inner surface of the model body. The surface vein body is located between the transparent adhesive layer and the inner surface of the model body. The structure and the color level of the blood vessel on the organ model are more consistent with the reality, so that the evaluation test of the image is more in line with the clinical requirements, the manufacturing is simple, the storage is convenient, the test cost can be reduced, the reutilization can be realized, the resource waste is avoided, and the continuity and the result stability of the evaluation test are good.

Systems, methods and software for scanning an ocular structure of an eye are provided. A method includes projecting a light onto the ocular structure, and scanning, by natural movements of the living eye, the light in a region of the living eye. Applicable ocular structures can include an ocular surface, a cornea, a sclera, an iris, a crystalline lens, an ocular fundus, a retina, a choroid, and a vitreous humor. A system includes a light source to create light, and optics to focus the light from the light source onto the ocular structure and to collect secondary light coming from the eye towards a detector. The system also includes a tracking system to register positions of the eye at different times, and a computer system to receive signals coupled from the tracking system representative of eye positions at different times and associate the signals with the tracking position.

The utility model provides a display device and a learning tablet, the display device comprises a display screen and an eye protection illumination module, the eye protection illumination module comprises a preset eye protection light source, and the eye protection illumination module is arranged in a reciprocating sliding mode relative to the display screen so as to be stored behind the display screen or extend out of the display screen area; and after extending out of the display screen area, the light source is started to irradiate human eyes. According to the application, the eye protection illumination module independent of the display screen is utilized to irradiate the human eyes, through the non-invasive photobiological regulation effect, the choroid thickness and the retinal metabolism are enhanced, the asthenopia is relieved, meanwhile, myopia development is inhibited from the source, and the incidence rate of myopia is effectively reduced.

An ocular implant system is described herein in which an implant (200) is deployed in the posterior space of an eye - e.g., the suprachoroidal space or the subconjunctival space or the intrascleral space - through an access in the anterior chamber (160) for reducing intraocular pressure in the eye. The shunt device (200) is implanted using an implantation device that includes a hollow shaft (330) mounted on a fixed shaft (320). The shunt device (200) is located in the distal end of the hollow shaft (330) and adjacent to the distal end of the fixed shaft (320) at a location behind the distal end of the hollow shaft. Once the distal end of the hollow shaft (330) and the shunt device (200) are at the desired depth within the posterior space, the hollow shaft is withdrawn over the fixed shaft through the access in the anterior chamber (160) towards the proximal end of the fixed shaft, leaving the shunt device in the posterior space.

A stent implant for treating glaucoma by intraocular fluid drainage from the anterior chamber, for example into the suprachoroidal space. The stent implant is designed to change in shape after being inserted into the eye, during which change the width and / or thickness or the flow cross-section is increased by for example 20%, in another example more than 200%, and in a further example by more than 400%, at least one point of the stent implant. In the case of intraocular fluid drainage from the anterior chamber into the suprachoroidal space, a cyclodialysis cleft which may open can be largely or completely closed. With appropriate adjustments, the stent implant can also be applied in trabecular, uveoscleral, uveolymphatic and subconjunctival applications for intraocular fluid drainage from the anterior chamber. The implant can even be used for direct intraocular fluid discharge from the anterior chamber onto the surface of the eye.

The present disclosure relates to a medicine depth delivery device, which comprises a delivery part with a containing structure for containing a medicine, a needle connected with the containing structure, and a positioning part sleeved on the needle, the positioning part having a positioning structure and a scale arranged at the bottom end thereof, the positioning structure comprising a first positioning structure and a second positioning structure, the first positioning structure and the second positioning structure being flipped towards the radial outside of the body relative to the body, the first positioning structure having a first opening with the body, the second positioning structure having a second opening with the body, and the opening directions of the first opening and the second opening being opposite to each other. By being provided with the positioning structure and the positioning part with the scale, the positioning part can be fixed to the desired position in the case of delivering the medicine to the choroid and scleral space, and the effect of high-precision depth delivery is achieved in combination with the previously measured scleral thickness.

Provided are formulations and methods for treating patients having AMD, by inhibiting formation or growth of drusen, and / or reducing number and / or size of drusen, while maintaining or restoring ellipsoid zone area in a human eye.

The invention discloses a red-light small-hole optical lens for preventing and controlling axial myopia and a manufacturing method of the red-light small-hole optical lens. Relates to the technical field of optical lenses, and comprises a lens base body and a plurality of optical functional areas arranged on the lens base body, each functional area has different light transmittances for 620-650 nm red light, and the light transmittances are gradually distributed from the center of the optical functional area to the edge of the optical functional area by 10%-99.99%. The optical function area comprises but is not limited to a three-area or four-area structure, and a red dot diffusion effect from deep to light is formed through cooperation of the light transmittance of all the areas. Red light with a specific wavelength can be projected to retina and choroid areas in a dispersion manner, and choroid blood circulation is improved through a photobiological effect, so that the growth of an ocular axis is inhibited. And the optical functional area is manufactured through a process of combining red light pulse laser internal micro-engraving or ultraviolet laser surface etching with high-transmittance red light film layer lamination. Red light treatment and daily glasses are combined, and all-weather and living myopia prevention and control are achieved.

The invention relates to an eye essence stock solution and a preparation method thereof. The eye essence stock solution comprises a traditional Chinese medicine compound extraction concentrated solution. The traditional Chinese medicine compound comprises ligusticum wallichii, liquorice, fructus lycii, salvia miltiorrhiza, nacre mother of pearl, caulis spatholobi, angelica sinensis, pseudo-ginseng, cornu cervi pantotrichum, crocus sativus, semen cassiae and selaginella tamariscina. According to the essence stock solution, through the synergistic interaction of all the components in the traditional Chinese medicine compound, the essence stock solution penetrates through skin to directly reach fundus, clears and activates channels and collaterals, warms channels and dispels cold, promotes blood circulation of eyes, effectively improves nutrition of tissues around the eyes, relaxes ciliary muscles which are tense and shrunk for a long time, and enables choroids to be hyperemia and thickened so as to play a role in regulating and controlling myopia.

Provided are formulations and methods for treating drusen and / or AMD, such that the risk of vitreous flare and lens opacity or lens haziness, e.g., cataract formation, is reduced or substantially eliminated.

Conventional ways of reducing pressure in the eye have inherent drawbacks and one such way to reduce these drawbacks is to provide an ocular drainage implant including a pliable plate which is so sized and shaped as to enable it to be positioned on a sclera surface or a sub-scleral space of an eye comprising a first exterior face and a second exterior face, with a plurality of apertures extending between the first and second faces, and a fluid drainage tube retaining structure; and a valve-less fluid drainage tube connected to the retaining structure and providing the implant with a longitudinal axis, the valve-less fluid drainage tube being adapted to drain fluid from an anterior chamber of the eye to the subconjunctival or the suprachoroidal space, wherein the retaining structure extends substantially across an entire dimension of the plate.

This invention discloses a method and system for quantitative analysis of the choroidal capillary layer, relating to the field of vascular imaging technology. The key technical points are: acquiring OCTA volume data; extracting en-face projection images from the OCTA volume data, where the en-face projection images reflect blood flow distribution information in the CC layer; performing dynamic thresholding on the en-face projection images to generate binarized or significantly enhanced images, obtaining the boundary position between the CC layer and the Sattler layer; mapping the boundary position back to the OCTA volume data; determining the lower boundary position of the CC layer in the structural B-scan image sequence corresponding to the OCTA volume data, thus completing the three-dimensional segmentation of the CC layer. This invention achieves stable, repeatable, and accurate definition of the three-dimensional anatomical range of the CC layer, overcoming the shortcomings of existing technologies that rely on fixed thresholds or single image modalities, resulting in subjective segmentation and poor individual adaptability.

This disclosure generally relates to the field of ophthalmic therapies, and more particularly to the treatment of various eye diseases and conditions by the non-surgical administration into a subject's eye of a pharmacological composition described herein containing a plasma kallikrein inhibitor. Avoralstat is included among the plasma kallikrein inhibitors. The compositions and methods include the administration of a plasma kallikrein inhibitor into the suprachoroidal space (SCS) of the eye.

The application discloses a choroid suprachoroidal injection device, and relates to the technical field of injection devices.The injection device comprises a silica gel ring, a mounting head base, a needle tube, a needle seat, a rubber plug, a first syringe, a first core rod, a second syringe and a second core rod.When the silica gel ring is attached to an eyeball, the first syringe is pulled out from the second syringe, a negative pressure is generated in the air suction cavity to enable the silica gel ring to be adsorbed to the eyeball, the needle tip of the needle tube pierces the sclera of the eyeball to the choroid, the first core rod is pushed into the first syringe, the rubber plug injects the medicine in the medicine injection cavity between the sclera and the choroid of the eyeball, so that the choroid suprachoroidal injection device can be adsorbed and fixed to the eyeball, the length of the needle tip of the needle tube extending out of the mounting head base can define the depth at which the needle tip of the needle tube pierces the eyeball, and the injection depth to the choroid can be accurately controlled, so that the eyeball is prevented from being easily misaligned and damaged when the medicine is injected.

The disclosure relates to ophthalmic implants, specifically a flexible, self-expanding spacer device deployable in subconjunctival, sub-Tenon's, or suprachoroidal spaces to manage intraocular fluids. The device addresses limitations of fixed-resistance drainage and fibrosis-related failure in glaucoma surgery by maintaining a controlled three-dimensional reservoir (bleb space) for aqueous humor outflow while minimizing tissue trauma. In one aspect, a shape-memory body transitions from a compressed, delivery-compatible state to an expanded configuration defining a convex internal volume, optionally with collapse-resistant reinforcements and tissue-engaging elements for atraumatic stabilization. Preferred embodiments include anterior relief geometry to avoid corneal contact and posterior flow-directing features to promote posterior bleb formation and uniform pressure control. A delivery member with a reduced-profile, tapered piercing tip and optional bent shaft enables minimally invasive ab externo implantation and controlled, coaxial deployment. Advantages include streamlined single-step delivery, stable long-term bleb architecture, reduced hypotony and fibrotic encapsulation, and compatibility with trabeculectomy and shunt-based outflow.

This invention relates to the field of biotechnology and discloses a method for screening drugs capable of preventing and / or treating posterior segment diseases of the eye. The method includes: first, decompressing the anterior chamber of an experimental animal; then, pre-establishing a "perforation-closure" channel in the sclera of the experimental animal; next, injecting the drug to be screened into the suprachoroidal space of the experimental animal through the "perforation-closure" channel in the sclera; and finally, evaluating the effectiveness of the drug in preventing and / or treating posterior segment diseases based on changes in the eye condition of the experimental animal. This invention reduces the incidence of ocular surface inflammation and improves safety by lowering intraocular pressure and creating a pre-closed scleral incision to prevent backflow of the injected AAV vector; it also provides a broader expression range and longer duration of action. Studies have shown that injecting shRNA targeting the TGF-β2 gene using the method of this invention inhibits myopia progression in a guinea pig model. The method provided by this invention is beneficial for screening gene therapy drugs related to posterior segment diseases.

Ocular implants, kits and methods are disclosed. In one arrangement, an implant comprises a frame deployable in the suprachoroidal space of an eye and configured to resiliently adopt an arched elongate shape to promote drainage of aqueous humor through the suprachoroidal space when the frame is deployed in the suprachoroidal space. Relative to an axis of elongation of the elongate shape: the frame has a first axial end and a second axial end; and the arched elongate shape defines a channel. The channel has a first axial opening at the first axial end of the frame, a second axial opening at the second axial end of the frame, and a longitudinal opening extending continuously from the first axial end to the second axial end.

The utility model provides a phototherapy lamp with a choroid thickening function, which relates to the field of lamps, and comprises a lamp housing, a main substrate is arranged in the lamp housing, a groove is arranged at the top of the lamp housing, a magnetic attraction charging device electrically connected with the main substrate is arranged in the groove, a lamp panel electrically connected with the main substrate is arranged below the main substrate in the lamp housing, and the lamp panel is electrically connected with the main substrate. A plurality of red light lamp beads with the dominant wavelength being 650 nm are arranged on the lamp panel, a lens is arranged at the bottom of the lamp shell, and a switch electrically connected with the main substrate is arranged on the lamp shell. The irradiation of 650nm red light lamp beads of the phototherapy lamp can promote blood circulation, and meanwhile, the irradiation of eyes can achieve the effects of thickening choroids and further inhibiting the growth of ocular axes.

The invention discloses a selenium-doped long-afterglow nano material as well as a preparation method and application thereof, and belongs to the technical field of biomedicine. Tumor cell inhibition experiments prove that the selenium-doped long-afterglow nano-material has dual effects of promoting normal cell proliferation and killing tumor cells, especially killing eye choroidal melanoma cells. Meanwhile, transition metal elements and / or lanthanide elements are selectively doped in the preparation process, so that the material has near-infrared I region and II region luminescence characteristics, meanwhile, compared with selenium doping, the afterglow performance of the material is obviously improved, and the material has important application significance in the fields of biomedical imaging and disease diagnosis. Compared with a traditional long-afterglow material which only has luminous performance and has no obvious effect on cells, the selenium-doped long-afterglow nano material provided by the invention has the physiological function of killing tumor cells, is small in size and easy to metabolize and absorb by a human body, and provides possibility for realizing integration of tumor disease diagnosis and treatment.